Dick Evan G. 4/A
4/A · Context Therapeutics Inc. · Filed Dec 17, 2021
Insider Transaction Report
Form 4/AAmended
Dick Evan G.
SVP of R&D
Transactions
- Conversion
Common Stock
2021-10-22+26,587→ 82,960 total - Conversion
Series Seed Preferred Stock
2021-10-22−26,587→ 0 total→ Common Stock (26,587 underlying)
Footnotes (3)
- [F1]Each share of Series Seed Preferred Stock had no expiration date and automatically converted into one share of Common Stock upon the closing of the Issuer's initial public offering.
- [F2]Includes 33,397 restricted stock units which fully vest on January 31, 2023.
- [F3]Fully vested.